Compare · AIKI vs HWKN
AIKI vs HWKN
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Hawkins Inc. (HWKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and HWKN operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- HWKN is the larger of the two at $3.57B, about 83.1x AIKI ($42.9M).
- HWKN has more recent analyst coverage (6 ratings vs 1 for AIKI).
- Company
- AIkido Pharma Inc.
- Hawkins Inc.
- Price
- $3.61+2.56%
- $171.40+3.55%
- Market cap
- $42.9M
- $3.57B
- 1M return
- -
- +11.94%
- 1Y return
- -
- +39.24%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 6
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Hawkins Inc.
Hawkins, Inc. blends, manufactures, and distributes chemicals and other specialty ingredients in the United States and internationally. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition. The Industrial segment offers industrial chemicals, products, and services to agriculture, chemical processing, electronics, energy, food, pharmaceutical, and plating industries. This segment primarily provides acids, alkalis, and industrial and food-grade salts. It also receives, stores, and distributes various chemicals, such as liquid caustic soda, sulfuric acid, hydrochloric acid, urea, phosphoric acid, aqua ammonia, and potassium hydroxide. In addition, this segment manufactures sodium hypochlorite and agricultural products, as well as various food-grade products that include liquid phosphates, lactates, and other blended products; repackages water treatment chemicals and bulk industrial chemicals; and performs custom blending of chemicals, and contract and private label bleach packaging. The Water Treatment segment offers chemicals, equipment, and solutions for potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool and agriculture water. The Health and Nutrition segment offers ingredient distribution, processing, and formulation solutions to manufacturers of nutraceutical, functional food and beverage, personal care, dietary supplement and other nutritional food, and health and wellness products. Its products portfolio includes minerals, botanicals and herbs, vitamins and amino acids, excipients, joint products, sweeteners, and enzymes. The company was founded in 1938 and is headquartered in Roseville, Minnesota.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest HWKN
- SEC Form 4 filed by Lange Douglas A.
- SEC Form 4 filed by Mangine David J.
- SEC Form 4 filed by Oldenkamp Jeffrey P.
- SEC Form 4 filed by Grahek Drew M.
- SEC Form 4 filed by Hawkins Patrick H.
- Amendment: SEC Form SCHEDULE 13G/A filed by Hawkins Inc.
- CEO AND PRESIDENT Hawkins Patrick H. gifted 1,040 shares and received a gift of 260 shares, decreasing direct ownership by 0.25% to 315,737 units (SEC Form 4)
- Hawkins, Inc. to Participate in Raymond James & Associates' Annual Institutional Investor Conference
- Director Faulconbridge James A bought $388,860 worth of shares (3,000 units at $129.62), increasing direct ownership by 6% to 52,407 units (SEC Form 4)
- Hawkins, Inc. Announces Milestone for its WaterSurplus NanoStack™ Membranes